You are here

Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Upland, California, 91786 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-70 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- The subject has a history of inadequate response to at least 1, but no more than 4, of
the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide,
cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Current Therapy With Any DMARD Or Biologic

NCT00147498
Pfizer
Completed
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Rheumatoid Arthritis
NCT02984020
All Genders
19+
Years
Multiple Sites
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6 weeks for the treatment of the signs and symptoms of subjects with active rheumatoid arthritis (RA).
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: CP-690,550
    Oral tablets administered at a dose of 5 mg BID for 6 weeks
  • Drug: CP-690,550
    Oral tablets administered at a dose of 15 mg BID for 6 weeks
  • Drug: CP-690,550
    30 mg BID for 6 weeks
  • Other: Placebo
    Placebo tablets
  • Experimental: 5 mg BID
    CP 690,550 5 mg BID
    Intervention: Drug: CP-690,550
  • Experimental: 15 mg BID
    CP 690,550 15 mg BID
    Intervention: Drug: CP-690,550
  • Experimental: 30 mg BID
    Oral tablets administered at a dose of 30 mg BID for 6 weeks
    Intervention: Drug: CP-690,550
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Other: Placebo


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
264
June 2006
June 2006   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • The subject has a history of inadequate response to at least 1, but no more than 4, of the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide, cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)

Exclusion Criteria:

  • Current Therapy With Any DMARD Or Biologic
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Brazil,   Canada,   Germany,   Italy,   Mexico,   Slovakia,   Spain,   United States
Austria
 
NCT00147498
A3921019
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now